Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery

Product Highlight

FIX&PERM Cell Fixation and Permeabilization Kit

Flow cytometric analyses with monoclonal antibodies were so far mainly restricted to cell surface molecules. Intracellular structures such as cytoplasmic or nuclear enzymes, oncoproteins, cytokines, immunoglobulins etc. were largely excluded from such studies. Also excluded from flow cytometric studies were cytoplasmic localizations of well-established membrane molecules like CD3 and CD22, which, in their cytoplasmic form, are the most reliable lineage markers in undifferentiated leukemia. With the FIX&PERM® Kit flow cytometric analysis of intracellular antigens has become as easy as surface antigen studies. The only prerequisite is the availability of suitable antibody conjugates. Most of the available monoclonal antibody conjugates can be used with the FIX&PERM® Kit, some determinants are sensitive, however, to the fixation step involved. This and the optimal fixation time have to be tested for each reagent.

News

Two more of our excellent products have been published by PubMed:

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Using Exalpha SPARC Antibody (Cat. No. X1867P)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Using Exalpha's FITC labeled anti PY20 Antibody (Cat. No. X1017)

Exalpha Biologicals, Inc.

Matrix Metalloproteinase 9 (MMP9)

  • Product Code: X2056M
  • Size: 200 µg
  • Availability: In Stock In Stock
  • Price (USD): $232

Cat #

X2056M		 Quantity:      

Data Sheet

Product Name

Matrix Metalloproteinase 9 (MMP9)

Synonyms

CLG4B; GELB; 92 kDa gelatinase; matrix metallopeptidase 9

Host/Source

Mouse

Clone

2C3

Isotype

IgG1

Product Type

Monoclonal Antibody

Reactivity

Human

Applications

Western Blot, Immunohistochemistry (Paraffin sections)

Purification

Protein A/G Chromatography

Size

200 µg

Price (USD)

$232

Background

The matrix metalloproteinases (MMP) are a family of peptidase enzymes responsible for the degradation of extracellular matrix components, including collagen, gelatin, fibronectin, laminin and proteoglycan. Transcription of MMP genes is differentially activated by phorbol ester, lipopolysaccharide (LPS) or staphylococcal enterotoxin B (SEB). MMP catalysis requires both calcium and zinc. MMP-9 (also designated 92-kDa type IV collagenase or gelatinase B) has been shown to degrade bone collagens in concert with MMP-1 (also designated interstitial collagenase, fibroblast collagenase or collagenase-1), and cysteine proteases and may play a role in bone osteoclastic resorption. MMP-1 is down-regulated by p53, and abnormality of p53 expression may contribute to joint degradation in rheumatoid arthritis by regulating MMP-1 expression.

Immunogen

Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with a synthetic peptide derived from the C-terminus of the human MMP9 protein and mouse myeloma Ag8563 cells.

Positive Control

Colon, oesophageal and gastric tissues. Stronger expression in tumor versus normal tissue.

Formulation

Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Target Molecular Weight

92 kDa

Product Image

Image Legend

Left: Immunohistochemical staining of paraffin embedded colon carcinoma using MMP9 antibody (Cat. No. X2056M). Antigen retreival using 10mM citrate buffer and microwave method was used. Right: Western blot using MMP9 antibody on recombinant human proenzyme MMP9 (400 ng/lane).

Database Links:

SwissProtP14780Human

References

1. Wang, L. et al. (2006). Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J. Neurosci. 26(22);5996-6003

2. Solmiari, S.B., et al. (2006). Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int. J. Cancer. 119(6);1403-1411

3. Chen, X., et al. (2005). Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells. Int. J. Cancer. 116(1);52-61